{"id":"d7a7f4aa-16a9-5d68-9c5d-513c03dfac56","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:taxane-low-quarter","predicate":"reported_relationship","statement":"Adjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"7d00656a-6e0c-5375-897e-95e4e98e49fd","mechanism_event_label":"Adjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial.","subject":{"id":"688519ff-ec38-5f8d-8788-0cffea6cfc33","slug":"human-taxane-baseline-carnitine","display_name":"Human taxane-trial baseline serum carnitine status","entity_type_key":"cellular_process"},"object":{"id":"d69d84d1-506e-5bc4-a03f-accb17c14662","slug":"human-taxane-neuropathy","display_name":"Human taxane-associated peripheral neuropathy severity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"7d00656a-6e0c-5375-897e-95e4e98e49fd","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:taxane-low-quarter-event","event_type":"experimental_observation","label":"Adjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial.","description":"### taxane-low-quarter\n\nAdjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial.\nThe baseline definition was not a validated clinical deficiency threshold and did not isolate plasma ALCAR as the causal factor. Adjusted week-24 FACT-NTX difference −2.3 points, P=0.007; baseline status was not associated with neuropathy in either arm.\nModel and exposure: Women receiving adjuvant paclitaxel/docetaxel; ALCAR 3 g/day for 24 weeks. Trial-defined deficiency was the lowest carnitine quartile.\nLimitations: Recorded association/adjustment only. Neither proves all patients were replete nor tests every clinically deficient population.\nReference: Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23733756/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3699727/ | https://doi.org/10.1200/jco.2012.44.8738 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"688519ff-ec38-5f8d-8788-0cffea6cfc33","slug":"human-taxane-baseline-carnitine","display_name":"Human taxane-trial baseline serum carnitine status","entity_type_key":"cellular_process"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"d69d84d1-506e-5bc4-a03f-accb17c14662","slug":"human-taxane-neuropathy","display_name":"Human taxane-associated peripheral neuropathy severity","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""},{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"randomized intervention","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"0727cb60-dd74-52d0-ac12-86697e75ac71","slug":"paclitaxel","display_name":"Paclitaxel","entity_type_key":"small_molecule"},"role":"chemotherapy context","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"93c810d6-7f5f-5591-8bb2-ad1897aa03f8","slug":"docetaxel","display_name":"Docetaxel","entity_type_key":"drug"},"role":"chemotherapy context","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Women receiving adjuvant paclitaxel/docetaxel; ALCAR 3 g/day for 24 weeks. Trial-defined deficiency was the lowest carnitine quartile.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Recorded association/adjustment only. Neither proves all patients were replete nor tests every clinically deficient population.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Adjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. | https://pubmed.ncbi.nlm.nih.gov/23733756/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3699727/ | https://doi.org/10.1200/jco.2012.44.8738","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference taxane-low-quarter; The baseline definition was not a validated clinical deficiency threshold and did not isolate plasma ALCAR as the causal factor. Adjusted week-24 FACT-NTX difference −2.3 points, P=0.007; baseline status was not associated with neuropathy in either arm.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"2adf7e25-50e7-51fc-929b-b65bbc265a61","evidence_kind":"source_excerpt","locator":"Lines 551-557","start_line":551,"end_line":557,"excerpt":"### taxane-low-quarter\n\nAdjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial.\nThe baseline definition was not a validated clinical deficiency threshold and did not isolate plasma ALCAR as the causal factor. Adjusted week-24 FACT-NTX difference −2.3 points, P=0.007; baseline status was not associated with neuropathy in either arm.\nModel and exposure: Women receiving adjuvant paclitaxel/docetaxel; ALCAR 3 g/day for 24 weeks. Trial-defined deficiency was the lowest carnitine quartile.\nLimitations: Recorded association/adjustment only. Neither proves all patients were replete nor tests every clinically deficient population.\nReference: Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23733756/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3699727/ | https://doi.org/10.1200/jco.2012.44.8738 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Women receiving adjuvant paclitaxel/docetaxel; ALCAR 3 g/day for 24 weeks. Trial-defined deficiency was the lowest carnitine quartile.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}